hVIVO plc Award of Share Options (2330M)
04 January 2019 - 9:02PM
UK Regulatory
TIDMHVO
RNS Number : 2330M
hVIVO plc
04 January 2019
hVIVO PLC
("hVIVO" or the "Company")
Award of Share Options
London, UK, 4 January 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, announces
that on 1st January 2019 it awarded the following options over
ordinary shares of 5.0p each in the Company to Shelley Fraser:
Name Position Number Exercise Date of Percentage
of Share price Vesting of issued
Options per Share ordinary
Awarded share capital
Finance Director 1 January
Shelley Fraser (PDMR) 250,000 5.0p 2022 0.1%
------------------ ---------- ----------- ---------- ---------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the persons discharging managerial responsibilities/persons
closely associated
a) Name Shelley Fraser
------------------------ -----------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/ Finance Director (PDMR)
status
------------------------ -----------------------------------------------
b) Initial notification/ Initial Notification
Amendment
------------------------ -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name hVIVO plc
------------------------ -----------------------------------------------
b) Legal Entity N/A
Identifier
------------------------ -----------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description Options over Ordinary Shares of 5 pence
of the financial each
instrument,
type of instrument
Identification ISIN: GB00B6ZM0X53
code
------------------------ -----------------------------------------------
b) Nature of Award of options over ordinary shares in
the transaction the Company
------------------------ -----------------------------------------------
c) Currency GBP
------------------------ -----------------------------------------------
d) Price(s) and PDMR Exercise Price Volume
volume(s) (p)
Shelley Fraser 5.0 250,000
--------------- --------
------------------------
e) Aggregated
information
- Aggregated Options over 250,000 ordinary shares
volume 5.0p
- Exercise
price
------------------------ -----------------------------------------------
f) Date of the 1st January 2019
transaction
------------------------ -----------------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
------------------------ -----------------------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300
Trevor Phillips (Executive Chairman)
Fleur Wood (Director, Investor Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting +44 203 727 1000
Simon Conway / Victoria Foster Mitchell
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial
platform to accelerate drug and vaccine development in respiratory
and infectious diseases. Leveraging human disease models in flu,
RSV, HRV and respiratory indications, the hVIVO platform captures
disease in motion, illuminating the entire disease life cycle from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted more than 50 clinical studies and inoculated
over 2500 volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUSVKRKKAARRR
(END) Dow Jones Newswires
January 04, 2019 05:02 ET (10:02 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024